{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:06:15Z","timestamp":1788854775848,"version":"build-2803163510"},"reference-count":21,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"unspecified","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim International GmbH"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,9,24]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess microvascular changes in nailfold capillaries in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who received nintedanib or placebo in a sub-study of the SENSCIS trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Nailfold capillaroscopy (NC) was performed at baseline and week 52. In the nintedanib and placebo groups, we measured capillary density (number of capillaries\/mm), giant capillaries, abnormal shapes and percentage of fingers with microhaemorrhages. In addition, capillary density was evaluated in patients who did\/did not have risk factors for rapid forced vital capacity (FVC) decline at baseline and who did\/did not have ILD progression (absolute decline in FVC % predicted &gt;5% or death) from baseline to week 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between baseline and week 52, no notable changes were observed in any NC measurement in the overall placebo or nintedanib groups. In patients with risk factors for rapid FVC decline (n=38), there was a numerical reduction in mean capillary density over 52 weeks with placebo, but it remained stable with nintedanib. Among patients who had ILD progression (n=11), there was a numerical increase in mean capillary density over 52 weeks with nintedanib, but it remained stable with placebo. There were no notable changes in capillary density among patients who did not have risk factors for rapid FVC decline at baseline or ILD progression at week 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In a substudy of the SENSCIS trial, numerical differences in changes in capillary density assessed by NC over 52 weeks may suggest a potential effect of nintedanib in patients at risk of ILD progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-005704","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:20:23Z","timestamp":1760700023000},"page":"e005704","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Nailfold capillaroscopy in patients with systemic sclerosis-associated interstitial lung disease: a substudy of the SENSCIS trial"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02597933","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6271-7945","authenticated-orcid":false,"given":"Vanessa","family":"Smith","sequence":"first","affiliation":[{"name":"Ghent University Hospital, Department of Rheumatology, Ghent University, Department of Internal Medicine and Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Centre (IRC), Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, University College London Division of Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4941-7926","authenticated-orcid":false,"given":"Ariane L","family":"Herrick","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Research, The University of Manchester, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK, and National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC), Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Ittrich","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Alves","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-0932","authenticated-orcid":false,"given":"Maurizio","family":"Cutolo","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Rheumatology, Division of Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2026010700551523000_11.4.e005704.1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1614915"},{"key":"2026010700551523000_11.4.e005704.2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/1573397114666180809121005","article-title":"The Role of Vascular Endothelial Growth Factor in Systemic Sclerosis","volume":"15","author":"Flower","year":"2019","journal-title":"Curr Rheumatol Rev"},{"key":"2026010700551523000_11.4.e005704.3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00161-2019","article-title":"Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases","volume":"54","author":"Wollin","year":"2019","journal-title":"Eur Respir J"},{"key":"2026010700551523000_11.4.e005704.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210823"},{"key":"2026010700551523000_11.4.e005704.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"2026010700551523000_11.4.e005704.6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/acr2.11483","article-title":"Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial","volume":"4","author":"Assassi","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2026010700551523000_11.4.e005704.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102458"},{"key":"2026010700551523000_11.4.e005704.8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.semarthrit.2017.02.006","article-title":"Sequential nailfold videocapillaroscopy examinations have responsiveness to detect organ progression in systemic sclerosis","volume":"47","author":"Avouac","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2026010700551523000_11.4.e005704.9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170485"},{"key":"2026010700551523000_11.4.e005704.10","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1093\/rheumatology\/keac079","article-title":"Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement\/progression?","volume":"61","author":"Vanhaecke","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026010700551523000_11.4.e005704.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151018"},{"key":"2026010700551523000_11.4.e005704.12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/rheumatology\/kead207","article-title":"Treatment with mycophenolate mofetil is associated with improved nailfold vasculature in systemic sclerosis","volume":"63","author":"Wildt","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026010700551523000_11.4.e005704.13","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002859","article-title":"Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression","volume":"9","author":"Khanna","year":"2023","journal-title":"RMD Open"},{"key":"2026010700551523000_11.4.e005704.14","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/rheumatology\/kez374","article-title":"Progression of nailfold capillaroscopic patterns and correlation with organ involvement in systemic sclerosis: a 12 year study","volume":"59","author":"Sulli","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2026010700551523000_11.4.e005704.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140276"},{"key":"2026010700551523000_11.4.e005704.16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/RHU.0000000000001798","article-title":"Is There a Link Between Nailfold Videocapillaroscopy and Pulmonary Function Tests in Systemic Sclerosis Patients?: A 24-Month Follow-up Monocentric Study","volume":"28","author":"Vilela","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"2026010700551523000_11.4.e005704.17","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14060635","article-title":"Low-Carbon Monoxide Diffusing Capacity, Patient-Reported Measures and Reduced Nailfold Capillary Density Are Associated with Interstitial Lung Disease in Systemic Sclerosis","volume":"14","author":"De Angelis","year":"2024","journal-title":"J Pers Med"},{"key":"2026010700551523000_11.4.e005704.18","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1002\/art.39718","article-title":"Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study","volume":"68","author":"Cutolo","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026010700551523000_11.4.e005704.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102394"},{"key":"2026010700551523000_11.4.e005704.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131284"},{"key":"2026010700551523000_11.4.e005704.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160592"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-005704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:55:32Z","timestamp":1767776132000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-005704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,17]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/rmdopen-2025-005704"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-005704","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}